After leading CinCor to exit, de Garidel finds next CEO role at Abivax
Plus: INKEF’s Bulthuis joins Syncona and updates from Rocket, NGM, SparingVision, Walden and more
After leading CinCor Pharma Inc. to its takeout by AstraZeneca plc (LSE:AZN; NASDAQ:AZN) this year, Marc de Garidel will become CEO and interim chair of Abivax S.A. (Euronext:ABVX), effective May 5. He succeeds Hartmut Ehrlich, who is retiring after serving as CEO since the French inflammatory disease company’s founding in 2013, and Corinna zur Bonsen-Thomas, who is stepping down as chair but will remain on the board. Prior to CinCor, de Garidel was CEO of Corvidia Therapeutics Inc. until its 2020 acquisition by Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO). Abivax plans to appoint a long-term chair this year.
Roel Bulthuis joined Syncona Ltd. (LSE:SYNC) as managing partner and head of investments. Bulthuis was most recently managing director at INKEF Capital, before which he was SVP and managing director of M-Ventures for almost a decade...